Kataria Saurabh, Rogers Sylvette, Bilal Usama, Baktashi Haisum, Singh Romil
Neurology, Ochsner Louisiana State University Health Shreveport, Shreveport, USA.
Neurology and Neurocritical Care, University of Missouri Health Care, Columbia, USA.
Cureus. 2022 Jan 18;14(1):e21374. doi: 10.7759/cureus.21374. eCollection 2022 Jan.
Mass vaccination against coronavirus disease 19 (COVID-19) has effectively controlled the pandemic and has been remarkably effective and safe. Reports of a few adverse events have been reported after post-marketing surveillance. We present a rare case of multiple sclerosis (MS) relapse in a female who presented with fatigue, involuntary eye movements, and numbness; autoimmunity following the COVID-19 vaccine has also been described. She was diagnosed with MS six years back and was in remission. She received her COVID-19 vaccine 18 days ago. Her clinical and radiological features confirmed the MS relapse. Her serology for COVID-19 immunoglobulin G (IgG) and IgM was positive, and she was managed with intravenous methylprednisolone and symptomatic management. Our case provides a possible association of vaccine-associated MS relapse; however, more evidence is warranted from future studies.
针对冠状病毒病19（COVID-19）的大规模疫苗接种有效地控制了疫情，并且非常有效且安全。上市后监测报告了一些不良事件。我们报告了一例罕见的女性多发性硬化症（MS）复发病例，该患者出现疲劳、不自主眼球运动和麻木；也有关于COVID-19疫苗接种后自身免疫的描述。她六年前被诊断为MS且处于缓解期。她在18天前接种了COVID-19疫苗。她的临床和影像学特征证实了MS复发。她的COVID-19免疫球蛋白G（IgG）和IgM血清学检测呈阳性，她接受了静脉注射甲基泼尼松龙治疗及对症处理。我们的病例提供了疫苗相关MS复发的一种可能关联；然而，未来的研究需要更多证据。
